2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1689

Anti-Peptidylarginine Deiminase 3/4 Cross-Reactive Antibodies: A Novel Biomarker with Clinical and Mechanistic Implications in Rheumatoid Arthritis
Abstract Number: 2530

Anti-Ribosomal P Antibodies in a Large Cohort of Autoimmune Hepatitis with No Evidence of Lupus: A Common Underlying Mechanism Targeting Liver?
Abstract Number: 1950

Anti-Signal Recognition Particle Autoantibody ELISA Development and Validation: Utility in Patients with Necrotizing Myopathy
Abstract Number: 1776

Anti-SSA/Ro Mediated Injury to the Endothelium Via Urokinase Plasminogen Activator Receptor/Tgfbeta Activation: Implications in the Pathogenesis of Congenital Heart Block
Abstract Number: 1992

Anti-TNF Therapies Improve Bone Mineral Density At the Lumbar Spine of RA Patients by Decreasing Disease Activity and Suppressing Serum RANKL Levels
Abstract Number: 782

Anti-TNF Therapy Slows Radiographic Progression of Ankylosing Spondylitis
Abstract Number: 1347

Anti-TNFá Discontinuation in Psoriatic Arthritis: Is It Possible After Achieving Minimal Disease Activity?
Abstract Number: 1945

Anti-Transcription Intermediary Factor 1-Gamma (TIF1-Υ) Autoantibody Detection by ELISA and Immunoprecipitation in a Prospective Myositis Cohort: Predictive Value for Cancer Associated Myositis
Abstract Number: 1949

Anti-Transcription Intermediary Factor 1-Gamma (TIF1-Υ) Autoantibody ELISA Development and Validation
Abstract Number: 1338

Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation
Abstract Number: 1202

Antibodies Against Porphyromonas Gingivalis Correlate with Rheumatoid Arthritis-Specific Auto-Immunity in Arthralgia Patients
Abstract Number: 177

Antibodies to Citrullinated Peptides in Tuberculosis
Abstract Number: 422

Antibodies to Citrulline From Rheumatoid Arthritis Patients Also Bind Homocitrulline
Abstract Number: 1286

Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Abstract Number: 1953

Antibodies to NXP-2 and Transcriptional Intermediary Factor-Gamma Identify Patients with Cancer-Associated Dermatomyositis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].